Skip to main content

Table 4 Multivariate analysis of potential risk factors associated with hepatitis in HBsAg-negative DLBCL patients

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Variate OR 95% CI P value
HBcAb (+) 3.27 1.25-8.59 0.016
ALT (>40 U/L) 4.22 1.43-12.49 0.009
AST(>45 U/L) NA NA 0.129
  1. OR, odds ratio; CI, confidence interval; NA, not applicable. Other abbreviations as in Table 1.